Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) just unveiled an update.
Lepu Biopharma Co., Ltd. has scheduled a board meeting for March 25, 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025, and to authorize their publication. The board will also consider recommending a final dividend, if any, and address other corporate matters, signaling an upcoming update on the company’s financial performance and potential shareholder returns.
The meeting underscores a key governance milestone in Lepu Biopharma’s financial calendar, as investors await clarity on earnings, dividend policy, and any additional business decisions that could influence the company’s capital allocation and market positioning. The announcement also reconfirms the current composition of the board, led by chairman and executive director Dr. Pu Zhongjie and chief executive officer Dr. Sui Ziye, along with non-executive and independent non-executive directors.
The most recent analyst rating on (HK:2157) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong under stock code 2157. It operates in the biopharma industry, focusing on the development and commercialization of innovative therapies, and is governed by a board comprising executive, non-executive and independent non-executive directors.
Average Trading Volume: 6,973,208
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.75B
See more data about 2157 stock on TipRanks’ Stock Analysis page.